About Matthew Sullivan, PhD

Dr. Matthew Sullivan is a licensed staff psychologist in the Behavioral Medicine Service in the Psychiatry Department at Massachusetts General Hospital. His clinical specialties include the use of cognitive behavioral therapy (CBT) to address anxiety, depression, and stress in the context of medical illness. His work also focuses on reducing harms related to substance use. Dr. Sullivan has specialized training in interventions to promote health behavior change, including delivering cognitive behavioral therapy for insomnia (CBT-I) and helping patients to quit smoking, increase physical activity, and change unhealthy eating. He has substantial clinical experience serving LGBTQ+ patients. Dr. Sullivan is Member of the Faculty at Harvard Medical School and is an affiliated researcher at Fenway Community Health, Boston.

Dr. Sullivan completed his undergraduate degree in Psychology and English at Williams College. He obtained his PhD in clinical psychology at the University of Connecticut, with specialization in Health Psychology and Quantitative Research Methods. As a predoctoral student, Dr. Sullivan trained for four years as a T32 Fellow in the Social Processes of HIV/AIDS. He completed his pre-doctoral and post-doctoral fellowships at Harvard Medical School/Massachusetts General Hospital.

Clinical Interests:



Mass General Psychiatry: Behavioral Medicine Program
One Bowdoin Square
9th Floor
Boston, MA 02114
Phone: 617-726-3423

Medical Education

  • Fellowship, Massachusetts General Hospital

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Sullivan is a clinical health psychologist with expertise in the cognitive-behavioral treatment (CBT) of substance use disorders (SUDs). As a researcher at Massachusetts General Hospital (MGH), his work focuses on the delivery of interventions for health behavior change among people who use drugs. Dr. Sullivan is funded through the Harvard Center for AIDS Research to investigate facilitators and barriers to uptake of efficacious biomedical harm reduction tools such as HIV pre-exposure prophylaxis.


Reviews: Comments and Ratings